Cited by 81Cardiovascular Syncope and Autonomic DisordersVestibular and auditory disordersHeart Rate Variability and Autonomic Control

Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study

Open access
Theodorakis, George N., Leftheriotis, Dionyssios, Livanis, Efthimios G., Flevari, Panagiota, Karabela, Georgia, Aggelopoulou, Nikolitsa, Kremastinos, Dimitrios Th.·2006·EP Europace

Abstract

AIMS: To compare the therapeutic efficacy of placebo, propranolol, and fluoxetine in patients with vasovagal syncope (VVS). METHODS AND RESULTS: Ninety-six consecutive patients with VVS were randomized to treatment with placebo, propranolol, or fluoxetine and followed-up for 6 months. Before and during treatment, they reported their syncopal and presyncopal episodes and graded their well-being, expressed as the general evaluation of life, general activities, and everyday activities (each scaled from 1 = very good to 5 = very bad). Two patients refused follow-up. Among the remaining 94, no difference between groups was observed regarding the distribution of time of vasovagal events (syncopes or presyncopes) during follow-up (log-rank test). No difference was also observed when syncopes and presyncopes were assessed separately. Eighteen patients discontinued therapy. Among the remaining 76 ('on-treatment' analysis), the mean time to a vasovagal episode (syncope or presyncope) was significantly longer in the fluoxetine group when compared with the two other groups (log-rank test, P < 0.05). A significant difference in favour of fluoxetine was also observed regarding presyncopes. The difference between groups regarding the syncope-free period was not significant. During therapy, patients' well-being was improved (decreased) only in the fluoxetine-group (13.4 +/- 0.7 vs. 15.4 +/- 0.9 before treatment, P < 0.01). CONCLUSION: Fluoxetine seems to be equivalent to propranolol and placebo in the treatment of VVS. However, it improves patients' well-being and might be more effective in reducing presyncopes and total vasovagal events in some patients with recurrent VVS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/europace/euj041

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [10]10. Grubb BP. Pathophysiology and differential diagnosis of neurocardiogenic syncope. Am J Cardiol 1999;84:3Q-9Q.
  2. [22]22. Grubb BP, Kosinski DJ. Serotonin and syncope: an emerging connection? Eur J Cardiac Pacing Electrophysiol 1995;5:306-14.

Cited by

Sorted by citations

Authors
Theodorakis, G. N., Leftheriotis, D., Livanis, E. G., Flevari, P., Karabela, G., Aggelopoulou, N., & Kremastinos, D. T.
Affiliations
Onassis Cardiac Surgery Center (GR)
Corresponding author
Theodorakis, George N.
Venue
EP Europace
Published
2006-02-13
Volume
8
Issue
3
Pages
193-198
ISSN
  • 1099-5129 (ISSN-L)
  • 1532-2092
OpenAlex
W2161502613
Cited by
81
References
31
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 2 · 2017: 11 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 7 · 2012: 8
FWCI
2.03
Type
journal article
Language
en
Open access
Locations
  • EP Europace (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Cardiovascular Syncope and Autonomic Disorders
  • Life Sciences › Neuroscience › Neurology › Vestibular and auditory disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
Keywords
vasovagal syncope, fluoxetine, propranolol, presyncope, syncope, treatment efficacy, well-being, recurrent syncope, beta-blockers, antidepressants
MeSH terms
Adrenergic beta-Antagonists, Adult, Attitude to Health, Double-Blind Method, Female, Fluoxetine, Humans, Male, Propranolol, Quality of Life, Recurrence, Selective Serotonin Reuptake Inhibitors, Syncope, Vasovagal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review